Oxlumo 94.5 mg/0.5 mL solution for injection. clinical trials

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)

This study, called ILLUMINATE-C, is looking at a new medicine called Oxlumo for people with a serious kidney and liver condition called Primary Hyperoxaluria Type 1 (PH1). It's a Phase 3 study to check if the medicine is safe and helps to reduce a harmful substance called oxalate in the body.